Wüthrich B
Respiration. 1979;37(4):224-31. doi: 10.1159/000194032.
Oral challenge tests with acetylsalicylic acid, tartrazine or benzoic acid were performed in 7 intolerant asthmatic patients after a 3-day treatment with either orally taken ketotifen (1 mg twice daily) or inhaled disodium cromoglycate (20 mg four times daily) at random. Protection was noted with ketotifen in 5, with DSCG in 3 patients. On the evaluation of the mean percentage of the maximum decline in the forced expiratory volume in 1 sec (FEV1) only ketotifen afforded significant protection statistically (p less than 0.05). All the intolerant asthmatics studies showed, as an immunological abnormity, a slight, but significant decrease of the C1-inhibitor levels. Moreover, in three out of these the alpha 1-antitrypsin serum values were under the lower normal range.
对7名不耐受的哮喘患者进行了口服乙酰水杨酸、酒石黄或苯甲酸激发试验,这些患者在随机接受为期3天的口服酮替芬(每日2次,每次1mg)或吸入色甘酸钠二钠(每日4次,每次20mg)治疗后进行试验。酮替芬使5名患者得到保护,色甘酸钠二钠使3名患者得到保护。在评估1秒用力呼气量(FEV1)的最大下降平均百分比时,只有酮替芬在统计学上提供了显著保护(p<0.05)。所有不耐受哮喘患者的研究均显示,作为一种免疫异常,C1抑制物水平有轻微但显著的降低。此外,其中3名患者的α1抗胰蛋白酶血清值低于正常范围下限。